A federal judge said the Trump administration has not presented enough evidence to justify labeling Anthropic a supply chain risk, casting doubt on the government's ban on its AI technology.
Samsung’s upcoming Galaxy Watch 9. | Photo: Dominic Preston / The Verge The Galaxy Watch 9 launches on August 7th, and not only does Costco have the best preorder incentives we’ve seen so far, the watch is also discounted. The deal includes the 40mm Watch 9 in cream or graphite, two wireless fast chargers for the watch, and a $50 Costco gift card, all for $339.99 — $40 less than the list price for the watch on its own directly from Samsung. The discounted price erases the $30 gen-to-gen price bump, and the extra chargers and gift card further sweeten the deal. If you aren’t a Costco member, a year of membership is only $65, which is less than the value of the free items in this purchase. Samsung Galaxy Watch 9 Where to Buy: $379.99 $339.99 at Costco (with $50 gift card and two chargers) There are some changes to the new watches from the Watch 8. The brand says the new chip, a Qualcomm Snapdragon Wear Elite, is built specifically for AI performance, and there are new health tracking features, plus better battery life, to boot. We got to spend some time with the Watch 9 and Watch 2 Ultra at Samsung’s July 2026 Unpacked event, so make sure to read our initial impressions of both watches if you’re curious about how the upgrades feel ahead of their early August launch.
With fingers in various highly lucrative pies, maybe the firm becoming LSE’s most valuable isn’t as fanciful as it seems Tufan Erginbilgiç, the chief executive of Rolls-Royce, seemed to be getting ahead himself when he said a year ago that the engine-maker had the potential to become the most valuable company on the London Stock Exchange. Yes, everyone knows about the remarkable turnaround. Rolls was a corporate calamity during the Covid shutdown of global aviation, then a tenfold increase in the share price followed under Erginbilgiç. But it still required a leap of imagination to think the firm could challenge the very top of the capitalisation charts one day. Continue reading...
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to apply to a newly established review board for approval. Once its treatment is rubber-stamped, the…